AKR1C1 overexpression leads to lenvatinib resistance in hepatocellular carcinoma

BACKGROUND: Lenvatinib is an orally administered drug that works as a multi-targeted tyrosine kinase inhibitor. It has been approved as a first-line drug after sorafenib in hepatocellular carcinoma (HCC). However, little is currently known about its treatment, targets, and possible resistance in HCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Cheng, Chang, Liang, Xu, Tianxin, Li, Xiaojun, Chen, Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331763/
https://www.ncbi.nlm.nih.gov/pubmed/37435231
http://dx.doi.org/10.21037/jgo-23-277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331763/
https://www.ncbi.nlm.nih.gov/pubmed/37435231
http://dx.doi.org/10.21037/jgo-23-277

Ejemplares similares